Effective today, life sciences industry leader Alice Pomponio has been named managing director of BrightEdge, our philanthropic impact fund that invests in companies to accelerate our mission to fight cancer.
Alice has served as a member of the board of directors of ACS CAN, chair of the ACS Eastern New England Board of Directors, and was a two-time chair of ACS CAN's Boston Research Breakfast.
BrightEdge is our donor-funded, philanthropic venture capital fund that invests in for-profit companies developing novel solutions to attacking cancer.
Alice is a faculty member at Harvard-MIT HST Sloan Healthcare Ventures, teaching biomedical innovation and healthcare entrepreneurship, a role she will retain. She previously was advisor, Red Sky Partners LLC, and managing director of Accendo, which she founded in 2018 to accelerate entrepreneurial consumer-facing approaches to patient access and affordability of quality care.
An expert in rare disease and precision oncology, she focuses on disruptive technology adoption and companion diagnostic / therapeutic co-development strategies with an eye towards value-based care. At Red Sky Partners, Alice advised high-growth life sciences and health tech companies on go-to-market and product value strategies.
Alice held prior strategy and operational leadership roles at Radius Health, AstraZeneca, and Sanofi Genzyme, where she launched multiple U.S. and global specialty products and championed orphan drug and health equity initiatives across the globe. Her public sector experience spans innovation, trade, and healthcare policy through roles in the UK Government and U.S. Office of Management and Budget.
She holds a Master of Public Policy from Harvard University and a Bachelor of Science in Biology from MIT. She serves on the Boards of Massachusetts Biotechnology Council, MassEcon, and PhagePro Inc.
"Alice’s extensive experience in life sciences and business, coupled with her passion for the American Cancer Society’s lifesaving mission, makes her uniquely positioned for this role," said Kael Reicin, our chief financial officer, to whom she reports.